CoChat
Sign Up
Cited by 321Cancer Risks and FactorsMenopause: Health Impacts and TreatmentsEndometrial and Cervical Cancer Treatments

The DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.

Body Mass Index, Hormone Replacement Therapy, and Endometrial Cancer Risk: A Meta-Analysis

Crosbie, Emma J., Zwahlen, Marcel, Kitchener, Henry C., Egger, Matthias, Renehan, Andrew G.·2010·Cancer Epidemiology, Biomarkers & Prevention
DOI 10.1158/1055-9965.epi-10-0832

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Background: Body mass index (BMI) is a risk factor for endometrial cancer. We quantified the risk and investigated whether the association differed by use of hormone replacement therapy (HRT), menopausal status, and histologic type. Methods: We searched MEDLINE and EMBASE (1966 to December 2009) to identify prospective studies of BMI and incident endometrial cancer. We did random-effects meta-analyses, meta-regressions, and generalized least square regressions for trend estimations assuming linear, and piecewise linear, relationships. Results: Twenty-four studies (17,710 cases) were analyzed; 9 studies contributed to analyses by HRT, menopausal status, or histologic type, all published since 2003. In the linear model, the overall risk ratio (RR) per 5 kg/m2 increase in BMI was 1.60 (95% CI, 1.52–1.68), P < 0.0001. In the piecewise model, RRs compared with a normal BMI were 1.22 (1.19–1.24), 2.09 (1.94–2.26), 4.36 (3.75–5.10), and 9.11 (7.26–11.51) for BMIs of 27, 32, 37, and 42 kg/m2, respectively. The association was stronger in never HRT users than in ever users: RRs were 1.90 (1.57–2.31) and 1.18 (95% CI, 1.06–1.31) with P for interaction = 0.003. In the piecewise model, the RR in never users was 20.70 (8.28–51.84) at BMI 42 kg/m2, compared with never users at normal BMI. The association was not affected by menopausal status (P = 0.34) or histologic type (P = 0.26). Conclusions: HRT use modifies the BMI-endometrial cancer risk association. Impact: These findings support the hypothesis that hyperestrogenia is an important mechanism underlying the BMI-endometrial cancer association, whilst the presence of residual risk in HRT users points to the role of additional systems. Cancer Epidemiol Biomarkers Prev; 19(12); 3119–30. ©2010 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-10-0832

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 85 references

Research works printed but not linked: 2

  1. World Health Organisation, BMI classification
  2. Tobias, 1999, sbe26: Assessing the influence of a single study in meta-analysis, Stata Tech Bull, 47, 15

Cited by

Sorted by citations

See all 321

Related

Metadata

Authors
Crosbie, E. J., Zwahlen, M., Kitchener, H. C., Egger, M., & Renehan, A. G.
Affiliations
University of Bern (CH)
ORCID
Venue
Cancer Epidemiology, Biomarkers & Prevention
Publisher
American Association for Cancer Research (AACR)
Published
2010-12-01
Volume
19
Issue
12
Pages
3119-3130
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
DOI
10.1158/1055-9965.epi-10-0832
OpenAlex
W2076975509
Cited by
321
References
85
Citations by year
2026: 21 · 2025: 19 · 2024: 15 · 2023: 24 · 2022: 25 · 2021: 25 · 2020: 26 · 2019: 15 · 2018: 19 · 2017: 20 · 2016: 21 · 2015: 33 · 2014: 23 · 2013: 21 · 2012: 9
FWCI
1.18
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Epidemiology Biomarkers & Prevention (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • BORIS (University Library Bern) (submittedVersion)
Funders
National Institute for Health and Care Research (CL-2007-06-005)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords
body mass index, endometrial cancer, hormone replacement therapy, obesity, menopausal status, histological subtypes, cancer risk modification, dose-response relationship, postmenopausal women, endometrial hyperplasia, endometrial adenocarcinoma, endometrioid carcinoma, serous carcinoma
MeSH terms
Female, Humans, Risk Factors, Cohort Studies, Body Mass Index, Endometrial Neoplasms, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review